Jpmorgan Chase & CO Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$144.95 - $152.29 $169 Million - $177 Million	1,165,134 Added 132.92%	2,041,718 $309 Million
Q2 2022 Aug 11, 2022	SELL	$83.14 - $145.99 $41 Million - $72 Million	-492,949 Reduced 35.99%	876,584 $128 Million
Q1 2022 May 11, 2022	SELL	$110.08 - $142.92 $2.82 Million - $3.66 Million	-25,592 Reduced 1.83%	1,369,533 $162 Million
Q4 2021 Feb 10, 2022	SELL	$99.73 - $148.48 $6.44 Million - $9.59 Million	-64,614 Reduced 4.43%	1,395,125 $192 Million
Q3 2021 Nov 12, 2021	BUY	$98.85 - $138.91 $144 Million - $203 Million	1,459,739 New	1,459,739 $203 Million

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $2.8B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.